CLRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Cellectar Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.12−0.02 (-1.75%)
Close on Oct 19, 2026
- Market cap
- $13.70M
- P/E (TTM)
- –
- Dividend yield
- –
Price history
Daily open, high, low, close and volume
| Date | Open | High | Low | Close | Change | Volume |
|---|---|---|---|---|---|---|
| Daily prices are not in StockData yet. This table fills in once an end-of-day price source is connected. | ||||||
Stock splits
From SEC filings
| Date | Ratio | Effect on per-share figures |
|---|---|---|
| Jun 24, 2025 | 1-for-30 reverse | Earlier per-share figures multiplied by 30 |
| Jun 24, 2025 | 1-for-30 reverse | Earlier per-share figures multiplied by 30 |
| Jul 22, 2022 | 1-for-10 reverse | Earlier per-share figures multiplied by 10 |
| Jun 27, 2022 | 1-for-10 reverse | Earlier per-share figures multiplied by 10 |
| Aug 10, 2018(first seen in filings) | 1-for-10 reverse | Earlier per-share figures multiplied by 10 |
| Jul 17, 2018 | 1-for-10 reverse | Earlier per-share figures multiplied by 10 |
| Mar 11, 2016(first seen in filings) | 1-for-10 reverse | Earlier per-share figures multiplied by 10 |
| Mar 7, 2016 | 1-for-10 reverse | Earlier per-share figures multiplied by 10 |
| Aug 4, 2014(first seen in filings) | 1-for-20 reverse | Earlier per-share figures multiplied by 20 |
| Jun 16, 2014 | 1-for-20 reverse | Earlier per-share figures multiplied by 20 |
| Apr 11, 2011 | 1-for-153 reverse | Earlier per-share figures multiplied by 153 |